Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease
- 1 November 2007
- journal article
- clinical trial
- Published by SAGE Publications in Antiviral Therapy
- Vol. 12 (8) , 1295-1304
Abstract
Background: Long-term effects of lamivudine treatment on chronic hepatitis B patients without advanced disease remain unknown. Our aim was to investigate the effects of long-term lamivudine treatment and lamivudine-resistant virus (YMDD) on the development of cirrhosis and hepatocellular carcinoma (HCC) in asymptomatic patients without advanced disease. Methods: One hundred and forty-two hepatitis B e antigen (HBeAg)-positive patients (median age: 33.9 years) on long-term lamivudine (median treatment duration: 89.9 months) and 124 HBeAg-positive controls (median age: 33.4 years) were prospectively followed up. Patients were monitored for the development of cirrhosis and HCC, liver biochemistry, hepatitis B virus (HBV) DNA levels, HBeAg seroconversion and hepatitis flares. YMDD mutations (YMDD-MT) were determined annually. Results: Lamivudine-treated patients had a significantly lower cumulative rate of development of cirrhosis and/or HCC compared with controls ( P=0.005). YMDD-MT occurred in 76.3% of patients after 8 years of lamivudine treatment. When compared with controls and patients with YMDD-MT, patients without YMDD-MT had the greatest reduction of HBV DNA and bilirubin levels, slowest decline of albumin level, highest rate of HBeAg seroconversion and lowest risk of hepatitis flare. Patients with YMDD-MT still had a lower risk for developing cirrhosis and/or HCC ( P=0.024) and a greater HBV DNA reduction ( P=0.001) in comparison with controls. Patients with YMDD-MT and controls had a similar chance of hepatitis flares and hepatic decompensation. Conclusions: Long-term lamivudine treatment was associated with a reduced chance of developing cirrhosis and HCC in patients without advanced disease. Although YMDD-MT reduced the benefits from lamivudine therapy, the outcome of these patients was still better than untreated patients.Keywords
This publication has 22 references indexed in Scilit:
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B PatientsGastroenterology, 2005
- The relationship between HBV‐DNA levels and cirrhosis‐related complications in Chinese with chronic hepatitis BJournal of Viral Hepatitis, 2005
- Prognostic determinants for chronic hepatitis B in Asians: therapeutic implicationsGut, 2005
- Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in MenJNCI: Journal of the National Cancer Institute, 2005
- Significance of Hepatitis B Genotype in Acute Exacerbation, Hbeag Seroconversion, Cirrhosis–Related Complications, and Hepatocellular CarcinomaHepatology, 2003
- Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infectionHepatology, 2002
- Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: Results of 24 weeks of therapyJournal of Medical Virology, 2002
- Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapyHepatology, 2001
- Long-term follow-up of patients with chronic hepatitis B treated with interferon alfaGastroenterology, 1997